Diatrizoic Acid

CHEMBL1201220 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
613.9 g/mol
LogP
1.8
Phase
4

An iodinated contrast medium used in various radiological imaging procedures to enhance the visibility of blood vessels and body cavities on X-rays and CT scans. It works because its iodine atoms strongly absorb X-ray radiation, creating bright white images of the structures it fills. Allergic reactions ranging from mild flushing to severe anaphylaxis are possible.

Molecular Weight

613.9100 g/mol

LogP

1.80

TPSA

95.50 Ų

Lipinski RO5

Pass

Mechanism of Action

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I

InChI

InChI=1S/C11H9I3N2O4/c1-3(17)15-9-6(12)5(11(19)20)7(13)10(8(9)14)16-4(2)18/h1-2H3,(H,15,17)(H,16,18)(H,19,20)

Molecular Formula

C11H9I3N2O4

HBD / HBA

3 / 4

Rotatable Bonds

3

Heavy Atoms

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

An iodinated contrast medium used in various radiological imaging procedures to enhance the visibility of blood vessels and body cavities on X-rays and CT scans. It works because its iodine atoms strongly absorb X-ray radiation, creating bright white images of the structures it fills. Allergic reactions ranging from mild flushing to severe anaphylaxis are possible.

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Yes, Diatrizoic Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201220. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 2140. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.